BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 25131958)

  • 1. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
    Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
    Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of novel chiral TBBt derivatives with hydroxyl moiety. Studies on inhibition of human protein kinase CK2α and cytotoxicity properties.
    Borowiecki P; Wawro AM; Wińska P; Wielechowska M; Bretner M
    Eur J Med Chem; 2014 Sep; 84():364-74. PubMed ID: 25036794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, docking and in vitro anticancer evaluation of some new benzopyrone derivatives.
    El-Ansary SL; Hussein MM; Abdel Rahman DE; Abdel Ghany LM
    Bioorg Chem; 2014 Apr; 53():50-66. PubMed ID: 24607350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
    Shi L; Wu TT; Wang Z; Xue JY; Xu YG
    Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and identification of unprecedented selective inhibitors of CK1ε.
    Silveira-Dorta G; Sousa IJ; Fernandes MX; Martín VS; Padrón JM
    Eur J Med Chem; 2015; 96():308-17. PubMed ID: 25899335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
    Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
    Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
    Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
    Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
    N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
    Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanidinium-based derivatives: searching for new kinase inhibitors.
    Diez-Cecilia E; Kelly B; Perez C; Zisterer DM; Nevin DK; Lloyd DG; Rozas I
    Eur J Med Chem; 2014 Jun; 81():427-41. PubMed ID: 24858546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.
    Mojzych M; Šubertová V; Bielawska A; Bielawski K; Bazgier V; Berka K; Gucký T; Fornal E; Kryštof V
    Eur J Med Chem; 2014 May; 78():217-24. PubMed ID: 24681986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
    Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
    Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase casein kinase 2-mediated upregulation of N-cadherin confers anoikis resistance on esophageal carcinoma cells.
    Ko H; Kim S; Jin CH; Lee E; Ham S; Yook JI; Kim K
    Mol Cancer Res; 2012 Aug; 10(8):1032-8. PubMed ID: 22767590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors.
    Parveen I; Khan P; Ali S; Hassan MI; Ahmed N
    Eur J Med Chem; 2018 Nov; 159():166-177. PubMed ID: 30290280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4(3H)quinazolinone analogues.
    Al-Suwaidan IA; Abdel-Aziz AA; Shawer TZ; Ayyad RR; Alanazi AM; El-Morsy AM; Mohamed MA; Abdel-Aziz NI; El-Sayed MA; El-Azab AS
    J Enzyme Inhib Med Chem; 2016; 31(1):78-89. PubMed ID: 25815668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
    Jin F; Gao D; Zhang C; Liu F; Chu B; Chen Y; Chen YZ; Tan C; Jiang Y
    Bioorg Med Chem; 2013 Feb; 21(3):824-31. PubMed ID: 23260578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
    Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors.
    Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P
    Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.